`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
`
`
` PF Prism CV
`
` Attention: Nadia Kirzecky
`
` Director, Worldwide Safety & Regulatory
`
`235 East 42nd Street
`
`
`
`New York, NY 10017-5755
`
`
`
`
`Dear Ms. Kirzecky:
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Application (sNDA) dated November 20, 2015,
`
`
`
`
`
`received November 20, 2015, and your amendments, submitted under section 505(b) of the
`
`
`
`
`Federal Food, Drug, and Cosmetic Act (FDCA) for Tygacil (tigecycline) Injection.
`
`
`This Prior Approval supplemental new drug application provides for a change to subsection 2.3,
`
`
`
`
`Dosage in Pediatric Patients of the labeling.
`
`
`
`
`APPROVAL & LABELING
`
` We have completed our review of this supplemental application, as amended. It is approved,
`
`
` effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
`
` text.
`
`CONTENT OF LABELING
`
`
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`
`automated drug registration and listing system (eLIST), as described
`
`
`at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.
`
`
`
`
`Content of labeling must be identical to the enclosed labeling text for the package insert with the
`
`
`addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as
`
`well as annual reportable changes not included in the enclosed labeling.
`
`
`
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`
`
`
`“SPL Standard for Content of Labeling Technical Qs and As
`
`at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/
`
`UCM072392.pdf
`
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDA 21-821/S-042
`
`
`
`
`
`Reference ID: 3952540
`
`

`

`
`
`
`
` NDA 21-821/S-042
`
` Page 2
`
`
`
` Also within 14 days, amend all pending supplemental applications that include labeling changes
`
` for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
` with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`
`
`
`
`changes approved in this supplemental application, as well as annual reportable changes and
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`should provide appropriate annotations, including supplement number(s) and annual report
`
`
`date(s).
`
`
` REPORTING REQUIREMENTS
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796­
`
`
`
`
`1203.
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Sumathi Nambiar, MD, MPH
`
`Director
`
`Division of Anti-Infective Products
`
`Office of Antimicrobial Products
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`ENCLOSURE:
`
`Content of Labeling
`
`
`
`
`
`Reference ID: 3952540
`
`

`

`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`SUMATHI NAMBIAR
`06/29/2016
`
`Reference ID: 3952540
`
`